Clinical Trials Logo
  1. Home
  2. Primary Graft Dysfunction
  3. NCT02032069
  4. Details
NCT02032069 Clinical Trial

Pneumoproteins Expression in the Organ Donor

Primary Graft Dysfunction Clinical Trial

Official title:
Pneumoproteins Expression in the Organ Donor

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02032069
Other study ID # B406201112693
Secondary ID
Status Completed
Phase N/A
First received January 6, 2014
Last updated March 13, 2016
Start date January 2013
Est. completion date January 2016

Study information
Verified date March 2016
Source University Hospital of Mont-Godinne
Contact n/a
Is FDA regulated No
Health authority Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Study type Observational

Clinical Trial Summary

Primary graft dysfunction, a form of reperfusion pulmonary edema that occurs early after lung transplantation, shares key clinical and pathological features with acute lung injury and its more severe form, the acute respiratory distress syndrome. However, in contrast to acute lung injury/acute respiratory distress syndrome, in which biomarkers in plasma, urine and lung edema fluid have prognostic and pathogenetic value, the role of biomarkers in primary graft dysfunction has been less thoroughly explored. We will try in this study de determine the rule of pneumoproteins in the donor organ on the pulmonary edema in the recipient.

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 70 Years
Eligibility Inclusion Criteria:

All the organ donors for lung grafts.

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Other:
• no intervention

Locations
Country Name City State
Belgium CHU Mont-Godinne Yvoir Namur

Sponsors (1)
Lead Sponsor Collaborator
University Hospital of Mont-Godinne

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Recipient with primary graft dysfunction one year No
See also
  Status Clinical Trial Phase
Recruiting NCT05375149 - Exhaled Breath Particles in Lung Transplantation
Terminated NCT04558333 - CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation
Recruiting NCT01605214 - Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant N/A
Terminated NCT01715883 - Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction Phase 2
Recruiting NCT01151826 - Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation N/A
Recruiting NCT05691205 - Identifying Optimal PEEP After Lung Transplantation N/A
Completed NCT01967953 - Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation Phase 1
Recruiting NCT00506532 - The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study Phase 2/Phase 3
Completed NCT06159933 - Primary Graft Dysfunction, Pronation, Bilateral Lung Transplants N/A
Recruiting NCT03156894 - Heart Transplant and Primary Transplant Dysfunction: a Retrospective Analysis of the Strasbourg Experience N/A
Recruiting NCT00457847 - Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
Recruiting NCT00552357 - Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
Withdrawn NCT04505878 - Perioperative Vitamin C Lung Transplant Phase 2